Predicting platinum-resistance in advanced ovarian cancer: defining patient and disease characteristics to improve treatment approaches at initiation of treatment or earlier in the course of the disease
When exploring factors associated with response to front-line platinum-based treatment of ovarian cancer, Stage IV disease was significantly associated with resistance. As platinum resistant patients have poorer survival and fewer treatment options, it is important to further define the biology and appropriate initial management of these patients.
Authors
- Matthew Monberg (ORCID: https://orcid.org/0009-0006-7462-4782)
- Dana M. Chase (ORCID: https://orcid.org/0000-0002-1073-8688)
- Elizabeth A. Szamreta (ORCID: https://orcid.org/0000-0001-7723-3388)
- Srinivas Annavarapu (ORCID: https://orcid.org/0000-0003-0976-9177)
- Junxin Shi
- Gregory Patton
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- University of California, Los Angeles (US)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-02-13
- DOI
- https://doi.org/10.3389/fonc.2026.1765220
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00